

Product

Amundi S&P World Health Care Screened UCITS ETF Dist

A Sub-Fund of AMUNDI ETF ICAV

IE000JKS50V3 - Currency: EUR

This Sub-Fund is authorised in Ireland.

Management Company: Amundi Ireland Limited (thereafter: "we"), a member of the Amundi Group of companies, is authorised in Ireland and regulated by the Central Bank of Ireland.

The CBI is responsible for supervising Amundi Ireland Limited in relation to this Key Information Document.

For more information, please refer to www.amundi.ie or call 01-4802000.

This document was published on 28/04/2026.

What is this product?

Type: Shares of a Sub-Fund of AMUNDI ETF ICAV, an Undertaking for Collective Investments in Transferable Securities (UCITS), established as an ICAV.

Term: The term of the Sub-Fund is unlimited. The Management Company may terminate the fund by liquidation or merger with another fund in accordance with legal requirements.

Objectives:

The Sub-Fund is passively managed.

The objective of the Sub-Fund is to track the performance of the S&P World Health Care Weighted & Screened Index (the "Index"). The anticipated level of the tracking error, under normal market conditions, is indicated in the prospectus of the Sub-Fund.

The Sub-Fund promotes environmental and/or social characteristics through among others, replicating an Index integrating an environmental, social and governance ("ESG") rating.

The Index is an equity index that measures the performance of eligible equity securities from the S&P World Health Care Index (the "Parent Index"). The Parent Index is designed to measure the performance of large and mid-cap health care companies in developed markets excluding Korea which make up approximately 85% of the total available capital. Health care companies are identified by reference to the GICS. The health care sector includes health care providers and services, companies that manufacture and distribute health care equipment and supplies, and health care technology companies. It also includes companies involved in the research, development, production and marketing of pharmaceuticals and biotechnology products. The Index is selected and weighted to enhance ESG profiles, and reduce carbon emission intensity, all compared to the Parent Index. The Index applies several ESG filters (e.g. exclusions filters to exclude companies involved in controversial business activities (e.g. controversial weapon), or involved in ESG controversies) and optimization constraints (GHG intensity reduction and identical S&P Global ESG Score or improvement of such score compared to the Parent Index).

The Index is a net total return index, meaning that dividends net of tax paid by the index constituents are included in the Index return. More information about the composition of the Index and its operating rules are available in the prospectus and at

<https://www.spglobal.com/spdji/en/supplemental-data/europe>

The Index value is available via Bloomberg (SPDSEHUN).

The exposure to the Index will be achieved through a direct replication, mainly by making direct investments in transferable securities and/or other eligible assets representing the Index constituents in a proportion extremely close to their proportion in the Index.

The Investment Manager will be able to use derivatives in order to deal with inflows and outflows and which relate to the Index or constituents of the Index for investment and/or efficient portfolio management. In order to generate additional income to offset its costs, the Sub-Fund may also enter into securities lending operations.

Intended Retail Investor: This product is intended for investors, with a basic knowledge of and no or limited experience of investing in funds seeking to increase the value of their investment over the recommended holding period with the ability to bear losses up to the amount invested.

Redemption and Dealing: The Sub-Fund's shares are listed and traded on one or more stock exchanges. In normal circumstances, you may deal in shares during the trading hours of the stock exchanges. Only authorised participants (e.g., selected financial institutions) may deal in shares directly with the Sub-Fund on the primary market. Further details are provided in the AMUNDI ETF ICAV prospectus.

Distribution policy: The Fund's amounts available for distribution (if any) will be distributed.

More Information: You may get further information about the Sub-Fund, including the prospectus, and financial reports which are available at and free of charge on request from: Amundi Ireland Limited at AMUNDI IRELAND LIMITED, One George's Quay Plaza, George's Quay, Dublin 2, Ireland.

The Net Asset Value of the Sub-Fund is available on www.amundi.ie

Depositary: HSBC Continental Europe.

Representative in Switzerland: CACEIS (Switzerland) SA, 35 Route de Signy, P.O. Box, 2259, CH-1260 Nyon .

Paying agent in Switzerland: CACEIS Bank, Montrouge, Nyon Branch/Switzerland, 35 Route de Signy, CH-1260 Nyon.

In Switzerland, the prospectus, the Key Information Document, the Articles of incorporation as well as the annual and semi-annual reports of this UCITS can be obtained, free of charge, from the representative in Switzerland.

What are the risks and what could I get in return?

RISK INDICATOR



The risk indicator assumes you keep the product for 5 years.

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movement in the markets or because we are not able to pay you.

We have classified this product as 4 out of 7, which is a medium risk class. This rates the potential losses from future performance at a medium level, and poor market conditions could impact our capacity to pay you.

Additional risks: Market liquidity risk could amplify the variation of product performances.

This product does not include any protection from future market performance so you could lose some or all of your investment.

Beside the risks included in the risk indicator, other risks may affect the Sub-Fund's performance. Please refer to the AMUNDI ETF ICAV prospectus.

PERFORMANCE SCENARIOS

The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average, and best performance of the Sub-Fund over the last 10 years. Markets could develop very differently in the future. The stress scenario shows what you might get back in extreme market circumstances.

What you get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted.

Recommended holding period : 5 years			
Investment EUR 10,000			
Scenarios		If you exit after	
		1 year	5 years
Minimum	There is no minimum guaranteed return. You could lose some or all of your investment.		
Stress Scenario	What you might get back after costs	€5,720	€4,850
	Average return each year	-42.8%	-13.5%
Unfavourable Scenario	What you might get back after costs	€8,180	€8,550
	Average return each year	-18.2%	-3.1%
Moderate Scenario	What you might get back after costs	€10,930	€17,570
	Average return each year	9.3%	11.9%
Favourable Scenario	What you might get back after costs	€12,910	€19,780
	Average return each year	29.1%	14.6%

The figures shown include all the costs of the product itself, but may or may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

This type of scenario occurred for an investment using a suitable proxy.

Favourable scenario: this type of scenario occurred for an investment between 31/07/2017 and 29/07/2022.

Moderate scenario: this type of scenario occurred for an investment between 31/12/2018 and 29/12/2023

Unfavourable scenario: this type of scenario occurred for an investment between 30/08/2024 and 23/04/2026 .

What happens if Amundi Ireland Limited is unable to pay out?

A separate pool of assets is invested and maintained for each Sub-Fund of AMUNDI ETF ICAV. The assets and liabilities of the Sub-Fund are segregated from those of other sub-funds as well as from those of the Management Company, and there is no cross-liability among any of them. The Sub-Fund would not be liable if the Management Company or any delegated service provider were to fail or default.

What are the costs?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

COSTS OVER TIME

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, and how long you hold the product. The amounts shown here are illustrations based on an example investment amount and different possible investment periods.

We have assumed:

- In the first year you would get back the amount that you invested (0 % annual return). For the other holding periods we have assumed the product performs as shown in the moderate scenario.

- EUR 10,000 invested.

Investment EUR 10,000		
Scenarios	If you exit after	
	1 year	5 years*
Total Costs	€24	€220
Annual Cost Impact**	0.2%	0.3%

* Recommended holding period.

** This illustrates how costs reduce your return each year over the holding period. For example it shows that if you exit at the recommended holding period your average return per year is projected to be 12.21% before costs and 11.93% after costs.

We do not charge an entry fee

If you are invested in this product as part of an insurance contract, the costs shown do not include additional costs that you could potentially bear.

COMPOSITION OF COSTS

One-off costs upon entry or exit		If you exit after 1 year
Entry costs*	We do not charge an entry fee for this product.	Up to 0 EUR
Exit costs*	We do not charge an exit fee for this product, but the person selling you the product may do so.	0.00 EUR
Ongoing costs taken each year		
Management fees and other administrative or operating costs	0.18% of the value of your investment per year. This percentage is based on actual costs over the last year.	18.00 EUR
Transaction costs	0.07% of the value of your investment per year. This is an estimate of the cost of buying and selling the underlying investments for the product. The actual amount depends on how much we buy and sell.	6.93 EUR
Incidental costs taken under specific conditions		
Performance fees	There is no performance fee for this product.	0.00 EUR

* Secondary Market: because the Sub-Fund is an ETF, Investors who are not Authorized Participants will generally only be able to buy or sell shares on the secondary market. Accordingly, investors will pay brokerage fees and/or transaction costs in connection with their dealings on stock exchange(s). These brokerage fees and/or transaction costs are not charged by, or payable to, the Sub-Fund nor the Management Company but to the investor own intermediary. In addition, the investors may also bear the costs of "bid-ask" spreads; meaning the difference between the prices at which shares can be bought and sold.

Primary Market: Authorized Participants dealing directly with the Fund will pay related primary market transaction costs.

How long should I hold it and can I take money out early?

Recommended holding period: 5 years is based on our assessment of the risk and reward characteristics and costs of the Sub-Fund.

This product is designed for medium-term investment; you should be prepared to stay invested for at least 5 years. You can redeem your investment at any time, or hold the investment longer.

Order Schedule: Details of dealing frequency can be found under "What is this product?". Please see the "What are the costs?" section for details of any exit fees.

On the Primary Market the Company may:

- Suspend the redemption of shares, if exceptional circumstances so require, considering the interests of investors.
- Manage liquidity risks, by (i) limiting how many shares are redeemed in a short amount of time if redemption requests reach a predefined threshold beyond which such requests can no longer be executed in the best interests of all investors ("Gates"), and (ii) applying anti-dilution tools (anti-dilution levy or partial or full swing pricing) to mitigate material dilution for remaining investors.

On the Secondary Market, investors will generally be able to sell their shares on the relevant stock exchange. Further details can be found in the Prospectus.

How can I complain?

If you have any complaints, you may:

- Call our complaints hotline on 01-4802000
- Mail Amundi Ireland Limited at One George's Quay Plaza, George's Quay, Dublin, Ireland
- E-mail to AILComplaints@amundi.com

In the case of a complaint you must clearly indicate your contact details (name, address, phone number or email address) and provide a brief explanation of your complaint. More information is available on our website www.amundi.ie.

If you have a complaint about the person that advised you about this product, or who sold it to you, they will tell you where to complain.

Other Relevant Information

You may find the prospectus, constitutional documents, key investor documents, financial reports, and further information documents relating to the Sub-Fund including various published policies of the Sub-Fund on our website www.amundi.ie. You may also request a copy of such documents at the registered office of the Management Company.

Past performance: You can download the past performance of the Sub-Fund over the last 5 years at www.amundi.ie.

Performance scenarios: You can consult the previous performance scenarios updated each month on www.amundi.ie.